Biodesix, Inc. (BDSX) - חוב לטווח ארוך להון

Biodesix, Inc. relies on a strong executive team that expertly commercializes oncology tests. Long-term credit leverage clearly demonstrates financial stability, where the 8.13 level records fresh values. Robotics and AI optimize DNA analysis, although physicians remain pivotal to diagnostics. However, slow insurance reimbursement adoption and high marketing expenses create risks of prolonged unprofitability.

Portfolio managers are closely monitoring the financial stability of Biodesix, Inc. (BDSX) amid the high costs of test certification. This ratio measures the company's reliance on long-term loans relative to its equity. The analysis of long-term debt to equity on GURU.Markets captures a current value of 8.13. Low leverage is critical for protecting biomarker patent portfolios, confirming the issuer's high financial autonomy and strong market position.